Indication Specific Reports

As per the data published by Centers for Disease Control and Prevention (CDC) in December 2022, oncological disorders (various types of cancer) have emerged as the second leading cause of death in the US. In fact, as per recent studies, the annual burden of oncological disorders is more than USD 185 billion in the US. In order to address the aforementioned challenge, various developers across the globe, have identified inhibition of enhancer of zeste homolog 2 (EZH2) as one of the potential targ...

Orthokeratology is defined as the use of custom designed (as per the patient’s needs) and fitted contact lenses that are used to improve vision. This is achieved by temporarily reshaping the patient’s cornea. Majority of these novel ortho-k lenses are worn at night, during the sleep cycle, to reshape the front surface of the eye. It is worth highlighting that the United States Food and Drug Administration (USFDA) has recently stated that ortho-k lenses are safe for use by patients be...

The “Bullous Pemphigoid: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Bullous Pemphigoid.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elem...

The “Dry Age-related Macular Degeneration: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dry Age-related Macular Degeneration.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual...

The “Cushing’s Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cushing’s Syndrome.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t...

The “Idiopathic Short Stature: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Idiopathic Short Stature.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t...

Demyelinating Polyneuropathy Market Overview The “Chronic Inflammatory Demyelinating Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current trea...

The “Familial Amyloid Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Familial Amyloid Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In ad...

The “X-linked Hypophosphatemia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of X-linked Hypophosphatemia.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition...

Tumor-induced Osteomalacia Market Overview The “Tumor-induced Osteomalacia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Tumor-induced Osteomalacia.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and marke...

The “Hidradenitis Suppurativa: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Hidradenitis Suppurativa. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to othe...

Amblyopia Market Overview The “Amblyopia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Amblyopia. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other...

Chronic Cough Market Overview The “Chronic Cough: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Cough. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addit...

The “Refractory Gout: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Refractory Gout.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements,...

The “C3 Glomerulopathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of C3 Glomerulopathy.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elemen...

The “Angiomatosis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Angiomatosis.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the st...

The “Giant Cell Arteritis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Giant Cell Arteritis. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elemen...

The “Plexiform Neurofibroma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Plexiform Neurofibroma. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other el...

The “Spinocerebellar Ataxias: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Spinocerebellar Ataxias. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other...

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry